14-day Premium Trial Subscription Try For FreeTry Free
$0.341
+0.0046 (+1.37%)
At Close: May 06, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 DRMA stock ended at $0.341. This is 1.37% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 5.62% from a day low at $0.336 to a day high of $0.355.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Dermata Therapeutics, Inc. prices

Date Open High Low Close Volume
May 06, 2024 $0.336 $0.355 $0.336 $0.341 13 911
May 03, 2024 $0.337 $0.355 $0.330 $0.336 20 488
May 02, 2024 $0.346 $0.346 $0.333 $0.340 30 977
May 01, 2024 $0.325 $0.340 $0.325 $0.333 6 886
Apr 30, 2024 $0.340 $0.350 $0.327 $0.327 75 558
Apr 29, 2024 $0.337 $0.342 $0.320 $0.342 70 347
Apr 26, 2024 $0.341 $0.358 $0.333 $0.343 16 646
Apr 25, 2024 $0.341 $0.341 $0.332 $0.340 9 618
Apr 24, 2024 $0.340 $0.357 $0.327 $0.357 16 200
Apr 23, 2024 $0.322 $0.356 $0.322 $0.340 19 497
Apr 22, 2024 $0.322 $0.351 $0.322 $0.351 37 750
Apr 19, 2024 $0.338 $0.355 $0.321 $0.321 28 441
Apr 18, 2024 $0.294 $0.358 $0.288 $0.338 276 446
Apr 17, 2024 $0.270 $0.295 $0.257 $0.295 128 933
Apr 16, 2024 $0.256 $0.300 $0.232 $0.267 2 147 374
Apr 15, 2024 $0.407 $0.407 $0.300 $0.300 282 610
Apr 12, 2024 $0.419 $0.419 $0.395 $0.411 52 058
Apr 11, 2024 $0.410 $0.422 $0.395 $0.400 57 057
Apr 10, 2024 $0.398 $0.420 $0.398 $0.419 18 880
Apr 09, 2024 $0.418 $0.420 $0.404 $0.412 21 798
Apr 08, 2024 $0.428 $0.440 $0.410 $0.425 138 757
Apr 05, 2024 $0.410 $0.440 $0.410 $0.415 54 920
Apr 04, 2024 $0.392 $0.444 $0.392 $0.414 93 612
Apr 03, 2024 $0.409 $0.414 $0.391 $0.403 59 270
Apr 02, 2024 $0.410 $0.420 $0.395 $0.415 39 006
Click to get the best stock tips daily for free!

About Dermata Therapeutics, Inc.

Dermata Therapeutics. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phas... DRMA Profile

Golden Star

Ticker Date Change Price
TMO May 02 0.403% $571.25
STNG May 02 0.699% $71.50
DLR May 02 2.58% $140.15
RF May 02 0.97% $19.64
INVH May 02 0.87% $34.50
SMAR May 02 2.24% $38.39
BIRK May 02 0.650% $44.61
FTSL May 02 0.217% $46.11
VCSH May 02 0.287% $76.71
VRNT May 02 2.44% $30.78
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT